Agomelatine: A novel antidepressant

Innovations in Clinical Neuroscience

Volumn 8, Issue 11, 2011, Pages 10-14

  Sansone, Randy A ^a,b   Sansone, Lori A ^c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b KETTERING MEDICAL CENTER   (United States)

^c WRIGHT PATTERSON AIR FORCE BASE   (United States)

Author keywords

Agomelatine; Antidepressant; Depression

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; CYTOCHROME P450 1A2; DOPAMINE; FLUOXETINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; NORADRENALIN; PAROXETINE; PLACEBO; SEROTONIN; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; VENLAFAXINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BEDTIME DOSAGE; BODY WEIGHT; CONSTIPATION; DIARRHEA; DIZZINESS; DOPAMINE RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; FATIGUE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR DEPRESSION; MENTAL HEALTH CARE; MIGRAINE; NAUSEA; NORADRENALIN RELEASE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP PATTERN; SOMNOLENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 84455210998     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-ofonset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
2. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 1994;272:1749-1756.
3. Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63 Suppl 8:24-34.
4. National Institute of Mental Health. Questions and answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study-background. http://www.nimh.nih.gov/trials/practiceal/stard/backgroundstudy.shtml. Accessed June 20, 2011.
5. Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60:1439-1445.
6. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry. 2009;166:599-607.
7. Rush AH, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23:627-647.
8. Davis LL, Wisniewski SR, Howland RH, et al. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend. 2010;107:161-170.
9. Silverstein B, Patel P. Poor response to antidepressant medication of patients with depression accompanied by somatic symptomatology in the STAR*D study. Psychiatry Res. 2011;187:121-124.
10. San L, Arranz B. Agomelatine: a novel mechanism of antidepressantaction involving the melatonergic and the serotonergic system. Eur Psychiatry. 2008;23:396-402.
11. Wikipedia. Agomelatine. http://en.wikipedia.org/wiki/Agomelatine. Accessed May 3, 2011.
12. Servier Laboratories. Valdoxan. http://www.valdoxan.com/index.php/valdoxan-package-leaflet-informationfo r-the-user/. Accessed May 3, 2011.
13. Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol. 2007;10:575-578.
14. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68:1723-1732.
15. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2c antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10:661-673.
16. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239-247.
17. Goodwin GM, Emsley R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebocontrolled trial. J Clin Psychiatry. 2009;70:1128-1137.
18. Hale A, Corral R-M, Mencacci C, et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol. 2010;25:305-314.
19. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010;30:135-144.
20. Kennedy SH, Emsley R. Placebocontrolled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16:93-100.
21. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo controlled studies on agomelatine. Int Clin Psychpharmacol. 2007;22:283-291.
22. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebocontrolled study. J Clin Psychopharmacol. 2008;28:561-566.
23. Millan MJ, Brocco M, Gobert A, et al. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5HT2c receptor blockade. Psychopharmacol. 2005;177:1-12.
24. Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacol. 2007;190:575-579.
25. Montgomery SA. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol. 2006;16:S633-S638.
26. Salva M-A Q, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007;10:691-696.
27. Kupfer DJ. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol. 2006;16:S639-S643.
28. Montgomery SA, Kennedy SH, Burrow GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, doubleblind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19:271-280.
29. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50mg) compared with paroxetine (20mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol. 2010;24:111-120.
30. Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28:329-333.